TY  - JOUR

T1  - A multicenter, randomized, blinded, phase III study of pasireotide LAR versus octreotide LAR in patients with metastatic neuroendocrine tumors (NET) with disease-related symptoms inadequately controlled by somatostatin analogs.

JO  - Journal of Clinical Oncology

PY  - 2013/05/20

AU  - Wolin EM

AU  - Jarzab B

AU  - Eriksson B

AU  - Walter T

AU  - Toumpanakis C

AU  - Morse M

AU  - Tomassetti P

AU  - Weber M

AU  - Fogelman DR

AU  - Ramage J

AU  - Poon D et al

ED  - 

DO  - DOI: 10.1200/jco.2013.31.15_suppl.4031

PB  - American Society of Clinical Oncology (ASCO)

VL  - 31

IS  - 15_suppl

SP  - 4031

EP  - 4031

Y2  - 2024/12/22

ER  -